Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway

Genes and Development

Volumn 24, Issue 24, 2010, Pages 2754-2759

  Kent, Oliver A ^a   Chivukula, Raghu R ^a   Mullendore, Michael ^a   Wentzel, Erik A ^a   Feldmann, Georg ^a   Lee, Kwang H ^a   Liu, Shu ^a   Leach, Steven D ^a   Maitra, Anirban ^a   Mendell, Joshua T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

microRNA; miR 143 145; Pancreatic cancer; Primary transcript; Ras

Indexed keywords

BINDING PROTEIN; MICRORNA; MICRORNA 143; MICRORNA 145; RAS RESPONSIVE ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE REPRESSION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; TUMOR PROMOTION;

ANIMALS; CELL LINE; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; MICE; MICRORNAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; TRANSCRIPTION FACTORS; ZEBRAFISH; ZEBRAFISH PROTEINS;

DANIO RERIO; MURINAE;

EID: 78650204499     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1950610     Document Type: Article

References (40)

1. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. 2007. Down-regulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 98: 1914-1920. (Pubitemid 350002197)
2. Ambros V. 2004. The functions of animal microRNAs. Nature 431: 350-355.
3. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. 2007. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908.
4. Boyd KE, Wells J, Gutman J, Bartley SM, Farnham PJ. 1998. c-Myc target gene specificity is determined by a post-DNA binding mechanism. Proc Natl Acad Sci 95: 13887-13892.
5. Caldas C, Kern SE. 1995. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 18: 1-6.
6. Calhoun ES, Hucl T, Gallmeier E, West KM, Arking DE, Maitra A, Iacobuzio-Donahue CA, Chakravarti A, Hruban RH, Kern SE. 2006. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res 66: 7920-7928.
7. Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, Jung J, Gao P, Dang CV, Beer MA, et al. 2009. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci 106: 3384-3389.
8. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X,Wang K,Wang G, Ba Y, et al. 2009. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28: 1385-1392.
9. Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F, Avances C, Villalba M, Culine S, Fajas L. 2009. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE 4: e7542. doi: 10.1371/journal.pone.0007542.
10. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR. 2009. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let- 7. EMBO J 28: 347-358.
11. Date S, Nibu Y, Yanai K, Hirata J, Yagami K, Fukamizu A. 2004. Finb, a multiple zinc finger protein, represses transcription of the human angiotensinogen gene. Int J Mol Med 13: 637-642.
12. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, et al. 2004. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 279: 52361-52365.
13. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. 2008. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759-764.
14. Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, et al. 2008. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57: 1420-1430.
15. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. 2007. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell 27: 91-105.
16. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134.
17. Hingorani SR, Tuveson DA. 2003. Ras redux: Rethinking how and where Ras acts. Curr Opin Genet Dev 13: 6-13.
18. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450.
19. Iliopoulos D, Hirsch HA, Struhl K. 2009. An epigenetic switch involving NF-kB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139: 693-706.
20. Kent OA, Mullendore M, Wentzel EA, Lopez-Romero P, Tan AC, Alvarez H, West K, Ochs MF, Hidalgo M, Arking DE, et al. 2009. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 8: 2013-2024.
21. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, et al. 2009. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
22. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T. 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci 105: 3903-3908. (Pubitemid 351723497)
23. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. 2003. Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun 301: 1038-1044.
24. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, et al. 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419.
25. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. 2007. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054. (Pubitemid 46214304)
26. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, et al. 2010. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 120: 1298-1309.
27. Lotterman CD, Kent OA, Mendell JT. 2008. Functional integration of microRNAs into oncogenic and tumor suppressor pathways. Cell Cycle 7: 2493-2499.
28. Maitra A, Hruban RH. 2008. Pancreatic cancer. Annu Rev Pathol 3: 157-188.
29. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. 2003. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891.
30. Mukhopadhyay NK, Cinar B, Mukhopadhyay L, Lutchman M, Ferdinand AS, Kim J, Chung LW, Adam RM, Ray SK, Leiter AB, et al. 2007. The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: Implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer. Mol Endocrinol 21: 2056-2070.
31. Park SW, Davison JM, Rhee J, Hruban RH, Maitra A, Leach SD. 2008. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. Gastroenterology 134: 2080-2090.
32. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, et al. 2006. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661.
33. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY. 2009. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci 106: 3207-3212.
34. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R. 2007. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590.
35. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. 2003. A comprehensive characterization of pancreatic ductal carcinoma cell lines: Towards the establishment of an in vitro research platform. Virchows Arch 442: 444-452.
36. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, et al. 2009. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323: 1747-1750.
37. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA. 2007. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452.
38. Thiagalingam A, De Bustros A, Borges M, Jasti R, Compton D, Diamond L, Mabry M, Ball DW, Baylin SB, Nelkin BD. 1996. RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas. Mol Cell Biol 16: 5335-5345.
39. Uren AG, Kool J, Matentzoglu K, de Ridder J, Mattison J, van Uitert M, Lagcher W, Sie D, Tanger E, Cox T, et al. 2008. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 133: 727-741.
40. Zhang L, Zhao J, Edenberg HJ. 1999. A human Raf-responsive zinc-finger protein that binds to divergent sequences. Nucleic Acids Res 27: 2947-2956.